^
Association details:
| Biomarker: | CDK12 mutation |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Xtandi (enzalutamide capsule) (Androgen receptor inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Comparison of ctDNA between African American and Caucasian patients with CRPC post abiraterone and/or enzalutamide.
Published date:
02/13/2023
Excerpt:
African Americans with CRPC post treatment with abiraterone and/or enzalutamide had a higher frequency of P/LP CDK12 and KIT mutations, which have both been shown to lead to aggressive clinical features and treatment resistance.
DOI:
10.1200/JCO.2023.41.6_suppl.35
Source:
Title:
CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors
Published date:
04/21/2020
Excerpt:
Of those who received first-line abiraterone and enzalutamide for metastatic castration-resistant prostate cancer (mCRPC; n = 34), 41.2% had a PSA response, and median PFS was 5.3 months….CDK12-altered prostate cancer is an aggressive subtype with poor outcomes to hormonal and taxane therapies as well as to PARP inhibitors.
DOI:
10.1200/po.19.00399
